| Sunday, June 21 |
7:00 - 8:00 AM |
Nexus Healthcare Education |
156 ABC
Thomas M. Menino Convention & Exhibition Center
|
Individualized Immunosuppression in Renal Transplant: Evidence, Strategies, & Best Practices
RSVP
|
Join leading experts for a dynamic, case-based symposium focused on advancing individualized immunosuppression strategies in renal transplant. Explore current maintenance regimens, including calcineurin inhibitors, mTOR inhibitors, belatacept, and antimetabolites, while evaluating their efficacy, safety, and long-term outcomes. Delve into conversion strategies for patients experiencing therapy failures, and examine emerging immunosuppression therapies, including novel combinations and investigational approaches shaping the future of transplant care. Engage with a multidisciplinary expert panel to discuss practical applications, patient-centered decision-making, and strategies to optimize long-term safety, adherence, and quality of life for renal transplant recipients. |
| Sunday, June 21 |
12:15 - 1:15 PM |
Natera |
156 ABC
Thomas M. Menino Convention & Exhibition Center
|
Cell-Free DNA: From Promise to Practice—How Far We’ve Come |
Join us for a journey through the evolution of donor-derived cell-free DNA (dd-cfDNA). From early research to today’s standard of care. Featuring expert perspectives this session bridges the gap between clinical data and real-world practice. Discover how current dd-cfDNA utilization strategies and future molecular frontiers are empowering clinicians to detect rejection earlier and improve long-term patient outcomes. |
| Sunday, June 21 |
12:15 - 1:15 PM |
Eledon Pharmaceuticals, Inc. |
157 ABC
Thomas M. Menino Convention & Exhibition Center
|
The Hidden Burden of Transplant Success: The Impact of Lifelong Immunosuppression in Organ Transplantation: Risks, Trade-offs, and Emerging Solutions
RSVP
|
Join transplant physicians and transplant patients at ATC for an industry sponsored symposium: “The Hidden Burden of Transplant Success: The impact of lifelong immunosuppression in Organ Transplantation: Risks, Trade-offs, and Emerging Solutions”. Sunday, June 21, 2026, 12:15–1:15 PM. Through panel discussion and shared clinical and patient perspectives, this symposium will examine the quality-of-life impact of CNIs and other immunosuppressive therapies, highlighting real-world experiences and the ongoing unmet needs in post-transplant care. |
| Sunday, June 21 |
12:15 - 1:15 PM |
CareDx |
210 BC
Thomas M. Menino Convention & Exhibition Center
|
TBA |
|
| Sunday, June 21 |
12:15 - 1:15 PM |
Merck & Co. |
252 AB
Thomas M. Menino Convention & Exhibition Center
|
Considerations for CMV Disease Prevention In Kidney Transplantation |
Discuss the burden of CMV infection and disease in kidney transplantation
Review AST guideline (2019) recommendations for CMV prevention in adult kidney transplant patients.
Review clinical data for an option to help prevent CMV disease in high-risk adult kidney transplant recipients. |
| Monday, June 22 |
7:00 - 8:00 AM |
Bridge to Life |
156 ABC
Thomas M. Menino Convention & Exhibition Center
|
The Next Era of Machine Perfusion: From Evidence to Adoption in Clinical Practice |
This session examines the next phase of machine perfusion in liver transplantation by connecting clinical evidence with real-world implementation in the U.S. post-commercialization setting. It reviews insights from the Bridge to HOPE trial and the clinical and mechanistic rationale for hypothermic oxygenated perfusion (HOPE). It will then explore how viability assessment during hypothermia is evolving from descriptive observation to objective decision-making, and conclude with a discussion of the economic and operational realities of implementing perfusion. |
| Monday, June 22 |
12:15 - 1:15 PM |
TransMedics |
156 ABC
Thomas M. Menino Convention & Exhibition Center
|
TBA |
|
| Monday, June 22 |
12:15 - 1:15 PM |
RMEI Medical Education LLC (Takeda) |
157 ABC
Thomas M. Menino Convention & Exhibition Center
|
Targeted Approaches to CMV Management: Alleviating the Patient Burden from Prevention to Refractory Disease
RSVP
|
Cytomegalovirus (CMV) can be a life-altering reality for patients after solid organ transplant (SOT). Limited antivirals and rising resistance make treatment a challenge. Join Drs. Deepali Kumar and Raymund R. Razonable as they share practical, evidence-based strategies to tackle the most common serious infectious complication after SOT. The faculty will be joined by a patient who will speak directly about how her transplant journey was complicated by CMV and what it means for her to navigate this challenging infection on her path towards healing. |
| Monday, June 22 |
12:15 - 1:15 PM |
Paragonix Technologies |
210 BC
Thomas M. Menino Convention & Exhibition Center
|
TBA |
|
| Monday, June 22 |
12:15 - 1:15 PM |
Hansa Biopharma |
Harbor Ballroom 1
The Westin Boston Seaport
|
TBA |
|
| Monday, June 22 |
12:15 - 1:15 PM |
Sanofi |
Harbor Ballroom 2 & 3
The Westin Boston Seaport
|
The Drop in Deceased Donor Kidney Transplants: Causes, Consequences, and Considerations |
The session reviews evidence, policy impacts, and innovative strategies to map pathways for the efficient and equitable use of challenging kidneys which can help lead to maximal life saving benefit.
Join us as we explore the causes and consequences of the recent decline in U.S. deceased donor kidney transplants.
|
| Tuesday, June 23 |
12:15 - 1:15 PM |
Biogen |
156 ABC
Thomas M. Menino Convention & Exhibition Center
|
Advancements in Antibody Mediated Rejection and Microvascular Inflammation of Kidney Allograft: Biology, Biomarkers, and Beyond |
Antibody mediated rejection (AMR) is a leading cause of kidney allograft failure, with no approved therapies and limited evidence based treatment guidance. Advancing AMR care requires improved understanding of disease biology, early and accurate detection, and more targeted therapeutic strategies. This symposium examines the roles of CD38 expressing immune cells in AMR and microvascular inflammation, reviews emerging biomarkers for patient identification, monitoring, and treatment response, and discusses evolving CD38 targeted investigational approaches. |
| Tuesday, June 23 |
12:15 - 1:15 PM |
Thermo Fisher Scientific |
252 AB
Thomas M. Menino Convention & Exhibition Center
|
TBA |
|
| Tuesday, June 23 |
12:15 - 1:15 PM |
Veloxis Pharmaceuticals |
Harbor Ballroom 2 & 3
The Westin Boston Seaport
|
From Reflection to Action: Adjusting Immunosuppressive Therapy to Overcome Long-Term Therapeutic Inertia in Kidney Transplantation
RSVP |
Kidney transplantation is currently the gold standard of care and provides patients with end-stage kidney disease the best chance for long-term, dialysis-free survival, but, in addition to challenges regarding organ availability, is the challenge of optimizing allograft survival over time. In this live event, the audience will have an opportunity to connect with their colleagues and experts to discuss real- world situations that can present challenges, complications, and decision points that may arise in the management of kidney transplant recipients. |